Search

for
Search:

Sort by

Research

990-1000 / 1000+ results

Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors and Antioxidants as Promising Drugs for the Treatment of Diabetic Complications

research Development of Novel Indole-Based Bifunctional Aldose Reductase Inhibitors/Antioxidants as Promising Drugs for the Treatment of Diabetic Complications

9 citations , May 2021 in “Molecules”

New indole-based compounds, particularly cemtirestat, show promise as dual-function drugs for diabetic complications.

research Effect of tofacitinib on the expression of noggin/BMP-4 and hair growth stimulation in mice

2 citations , October 2018 in “Archives of Dermatological Research”

Tofacitinib helps mice grow more hair by increasing noggin and BMP4 levels, possibly better than minoxidil.

Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study

research Oral Tofacitinib and Systemic Corticosteroids, Alone or in Combination, in Patients With Moderate-to-Severe Alopecia Areata: A Retrospective Study

8 citations , June 2022 in “Frontiers in Medicine”

Both individual and combined treatments of tofacitinib and corticosteroids can help regrow hair in moderate-to-severe alopecia areata, but ongoing treatment may be necessary.

research 075 Clinical investigation of JAK inhibitor Tofacitinib in scarring alopecias

1 citations , April 2017 in “Journal of Investigative Dermatology”

Tofacitinib may slow hair loss in scarring alopecias but is unlikely to regrow significant hair.

research Treatment of alopecia universalis with topical Janus kinase inhibitors – a double blind, placebo, and active controlled pilot study

49 citations , August 2018 in “International Journal of Dermatology”

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

research Tyrosine Kinase Inhibitors – A Review on Pharmacology, Metabolism and Side Effects

508 citations , June 2009 in “Current drug metabolism”

Tyrosine kinase inhibitors effectively treat cancers but often cause skin and other side effects.

Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)

research Efficacy, Safety, and Tolerability of Upadacitinib in Adults and Adolescents With Severe Alopecia Areata: Results From the Randomized, Placebo-Controlled, Double-Blind Phase 3 Program (UP-AA)

November 2025 in “SKIN The Journal of Cutaneous Medicine”

Upadacitinib effectively treats severe alopecia areata and is safe.

research Treatment of Lichen Planopilaris With Abrocitinib

1 citations , February 2025 in “International Journal of Dermatology”

Abrocitinib may effectively treat Lichen Planopilaris.

research Characteristics and Outcomes of Patients on Tofacitinib for Alopecia Areata or Rheumatoid Arthritis: A Retrospective Cohort Study

January 2024 in “Pharmacoepidemiology”

Patients with rheumatoid arthritis using tofacitinib had more serious side effects than those with alopecia areata.

research Observation and consideration on using of JAKi in clinical trials in times of COVID ‐19

June 2020 in “Dermatologic therapy”

Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.

← Previous page